International Trachoma Initiative and the Task Force for Child Survival and Development Announce New Merger to Eliminate Blinding Trachoma and Fight Against Other Neglected Tropical Diseases
“ITI is excited by the enormous potential that this merger brings to eliminating blinding trachoma,” said
ITI was created in 1998 through a public-private partnership of the Edna McConnell Clark Foundation and Pfizer, and since then, has been the only global organization dedicated exclusively to the elimination of blinding trachoma.
“Pfizer is confident that the merger between ITI and the Task Force is a positive step forward in ridding the world of blinding trachoma. Pfizer is pleased with the progress we have made with our partners over the last ten years — providing over a billion dollars of pharmaceutical and financial donations — that has helped break the cycle of poverty trachoma imposes on millions of families and communities world-wide. We look forward to continuing our support and working through ITI and its Trachoma Expert Committee to provide the Zithromax that will be needed to eliminate blinding trachoma by 2020 and restore the health and well-being of families now and generations to come,” said
“The mission and goals of ITI are a strong complement to the Task Force mission,” stated
ITI is a major proponent and facilitator of the SAFE strategy to prevent, treat and ultimately eliminate blinding trachoma through Surgery, Antibiotics, Facial cleanliness, and Environmental improvements. The
SOURCE The International Trachoma Initiative (ITI)